Immunomodulatory drugs (IMiDs), like thalidomide, lenalidomide and pomalidomide, have been successfully used as first-line therapeutics in the treatment of multiple myeloma (MM) in the past two decades. This study identifies the IMiD-induced destabilization of the CD147/MCT1 membrane complex as a novel mechanism, by which IMiDs exert their versatile anti-tumor effects. Furthermore, it establishes CD147 and MCT1 both as valuable predictive markers for IMiD-response and as attractive therapeutic targets in the therapy of IMiD-resistant of refractory MM patients.
«
Immunomodulatory drugs (IMiDs), like thalidomide, lenalidomide and pomalidomide, have been successfully used as first-line therapeutics in the treatment of multiple myeloma (MM) in the past two decades. This study identifies the IMiD-induced destabilization of the CD147/MCT1 membrane complex as a novel mechanism, by which IMiDs exert their versatile anti-tumor effects. Furthermore, it establishes CD147 and MCT1 both as valuable predictive markers for IMiD-response and as attractive therapeutic t...
»